Back to results
US 2026/0216259 A1Published application
Novel lactococcus lactis subsp. lactis strain and use thereof
AssigneeWon Yong Kim
InventorsWon Yong Kim, Kiyoung Kim
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeWon Yong Kim
InventorsWon Yong Kim, Kiyoung Kim
Estimating the term…
The present invention relates to a novel strain of Lactococcus lactis subsp. lactis LB1022 strain and uses thereof. The Lactococcus lactis subsp. lactis LB1022 strain, which is a novel strain isolated from fermented dairy products, is a useful functional lactic acid bacterium with excellent acid tolerance, bile tolerance, and intestinal epithelial cell adhesion ability, and inhibits the production of any one inflammatory factor selected from the group consisting of nitric oxide (NO), tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), and interleukin-1β (IL-1β), and inhibits the gene expression of p65 or p50 in the nuclear factor kappa B pathway (NF-kB pathway), thereby exhibiting an excellent anti-inflammatory effect. Therefore, a composition comprising, as active ingredients, live bacteria, dead bacteria, or a culture medium thereof of the Lactococcus lactis subsp. lactis LB1022 strain may be utilized for the prevention, treatment, or amelioration of inflammatory diseases.
1-10. (canceled)
The pharmaceutical composition of claim 28, wherein the at least one condition is an allergic disease, wherein the allergic disease is at least one disease selected from the group consisting of allergic dermatitis, atopic dermatitis, asthma, and allergic rhinitis.
(canceled)
The health functional food composition of claim 29, wherein the at least one condition is an allergic disease, wherein the allergic disease is at least one disease selected from the group consisting of allergic dermatitis, atopic dermatitis, asthma, and allergic rhinitis.
14-21. (canceled)
A health functional food composition for gastrointestinal protection, comprising as an active ingredient, live bacteria, dead bacteria or a culture medium of Lactococcus lactis subsp. lactis LB1022 strain with Accession Number KCTC 15324BP.
23-25. (canceled)
The pharmaceutical composition of claim 28, wherein the at least one condition is a stress-related disease selected from the group consisting of stress-related gastritis, stress-related diabetes, stress-related headache, stress-related tension, stress-related anxiety, and stress-related depression.
The pharmaceutical composition of claim 28, wherein the at least one condition is a stress-related disease, wherein the pharmaceutical composition has a modulating effect to alleviate or reduce stress.
A pharmaceutical composition for preventing or treating at least one condition selected from the group consisting of an inflammatory disease, an allergic disease, skin damage, obesity, diabetes, muscle loss, gout, and a stress-related disease, comprising as an active ingredient, live bacteria, dead bacteria, or a culture medium of Lactococcus lactis subsp. lactis LB1022 strain with Accession Number KCTC 15324BP.
A health functional food composition for preventing or reducing at least one condition selected from the group consisting of an inflammatory disease, a hangover, a liver dysfunction, an allergic disease, obesity, diabetes, muscle loss, gout, comprising as an active ingredient, live bacteria, dead bacteria, or a culture medium of Lactococcus lactis subsp. lactis LB1022 strain with Accession Number KCTC 15324BP.
A pharmaceutical composition comprising Lactococcus lactis subsp. lactis LB1022 strain with Accession Number KCTC 15324BP.
A health functional food composition comprising Lactococcus lactis subsp. lactis LB1022 strain with Accession Number KCTC 15324BP.
Dependencies are inferred from the claim text.